EXACT SCIENCES CORP: Shareholders Approve Landmark Merger with Abbott Laboratories

Event Description (what happened): On February 20, 2026, Exact Sciences Corp. (NASDAQ: EXAS) shareholders gave their resounding approval to the previously announced merger agreement with healthcare giant Abbott Laboratories (NYSE: ABT). This crucial vote paves the way for Abbott to acquire Exact Sciences in a deal valued at approximately $15 billion. Exact Sciences shareholders will receive $100 per share, split evenly between cash and Abbott common stock. This represents a substantial premium over Exact Sciences' stock price before the initial announcement on November 15, 2025.

Event Date/Timeline: Shareholders approved the merger on February 20, 2026. This follows the initial merger agreement announcement on November 15, 2025. Both companies expect the merger to close in mid-2026, pending regulatory approvals and other standard closing conditions.

Impact Assessment (who/what is affected): This acquisition strategically strengthens both companies' positions in the diagnostics market.

• For Exact Sciences: Joining Abbott gives Exact Sciences access to a global distribution network, significantly expanded research and development capabilities, and greater capital resources. This integration will accelerate the reach of Exact Sciences' innovative cancer detection tests, like the widely recognized Cologuard for colon cancer, and could expedite new diagnostic solutions.
• For Abbott Laboratories: Acquiring Exact Sciences immediately strengthens Abbott's diagnostics portfolio, adding a leading position in cancer screening and precision oncology. Exact Sciences' established market presence and pipeline of early detection tests highly complement Abbott's existing diagnostic platforms, offering diversification and growth opportunities in a critical healthcare segment.

Impact on Key Stakeholders:

• Exact Sciences (EXAS) Shareholders: Once the merger closes, you will receive the agreed $100 per share consideration, split evenly between cash and Abbott stock. The stock price will likely trade very close to this offer price until closing, reflecting market confidence in the deal.
• Abbott Laboratories (ABT) Shareholders: This acquisition is a significant investment and strategic expansion. While it involves a substantial outlay, the long-term benefits should include enhanced market share, diversified revenue streams, and potential synergies.
• Customers (Patients & Doctors): The merger may lead to wider availability and potentially lower costs for Exact Sciences' diagnostic tests, leveraging Abbott's extensive infrastructure and global reach. Increased investment in R&D under Abbott could also accelerate the introduction of new, life-saving diagnostic tools.
• Employees: While integration always brings changes, this merger could open new career opportunities within the larger Abbott organization, alongside potential shifts in roles and company culture.

Financial Impact (if applicable): The deal totals approximately $15 billion. Exact Sciences shareholders will receive $100 per share, split evenly between cash and Abbott common stock. Abbott expects the acquisition to boost its earnings within the first full year after closing.

Key Takeaways for Investors: Now that shareholders have approved the merger, the main remaining hurdle is regulatory approval. Both companies are actively seeking clearances from antitrust authorities like the U.S. Federal Trade Commission (FTC) and the Department of Justice (DOJ), and other international bodies. Investors should watch for official announcements on these regulatory milestones.

• Opportunity (Arbitrage): If you own EXAS stock, the current trading price might be slightly below the $100 per share offer. This small difference, known as an arbitrage spread, offers a potential low-risk gain if the merger closes.
• Primary Risk (Regulatory Failure): The biggest risk is that regulatory bodies might not approve the merger, or could impose conditions that make the deal less attractive and lead to its termination. If this happens, Exact Sciences' stock price would likely fall significantly, possibly returning to pre-announcement levels.
• Other Risks: Delays in closing, challenges in integrating the two companies, or unforeseen market conditions could also impact the deal's outcome or the Abbott stock value.
• Action for EXAS Shareholders: Understand the specific terms of the merger, including the cash and stock components, and closely monitor regulatory developments.
• Action for ABT Shareholders: Evaluate how this acquisition fits into Abbott's long-term strategy and its potential impact on the company's financial performance and future growth.

This merger marks a transformative moment for Exact Sciences, marking its transition from an independent public company to a key part of a global healthcare leader. Always conduct your own research and consider consulting a financial advisor before making investment decisions.